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participants reported their history of depressive episodes and, if relevant,
the number of episodes. Volumetric assessment of the hippocampus was
performed using a 3-dimensional MRI sequence. Total hippocampal vol-
umes were calculated with correction for head size and gender. Subjects
with volumes below the 25th percentile of the distribution were defined as
having a small hippocampus (n128). All subjects were followed for
development of AD. The diagnosis of AD was made according to inter-
nationally accepted criteria. Results: A history of depressive episodes was
reported by 142 (27.8%) subjects, with 85 reporting one episode and 50
reporting 2 or more episodes. Logistic regression analyses adjusted for age,
gender, education, memory complaints, and MMSE score, showed that
subjects with a history of depression were less likely to have a small
hippocampus than those without such a history (OR 0.63; 95%CI 0.38-
1.05). The OR of having a small hippocampus associated with 1 episode
versus none was 0.74 (95%CI 0.41-1.33) and 2 versus none 0.42 (95%CI
0.18-0.98) (p-trend 0.03). After an average of 6 years of follow-up, 34
subjects developed AD. Cox regression analyses with adjustment for the
same covariates showed that subjects with a history of depression had an
increased risk of AD (HR 2.42; 95%CI 1.15-5.10). The HR of AD asso-
ciated with 1 episode versus none was 2.14 (95%CI 0.81-5.64), and 2
versus none 2.54 (95%CI 0.90-7.16) (p-trend 0.04). Conclusion: This
study suggests that elderly with a history of depressive episodes are less
likely to have a small hippocampus, whereas prospectively they have an
increased risk of AD. If replicated, future research should investigate what
mechanisms may underly these seemingly contradictory associations.
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Background: The relationship between cancer and dementia is still
poorly understood. Recent studies showed that cancer survivors fre-
quently experience short-term cognitive deficits, but it is unknown
whether these deficits last or whether they worsen over time, as well as
the cause of this association. Objective(s): To evaluate whether pa-
tients with a diagnosis of dementia have a higher frequency of malig-
nant neoplasia in their clinical history, and if there is an association
between cancer history and dementia subtype. Methods: Medical his-
tory of 470 consecutive subjects evaluated in our Centre for Cognitive
Disturbances were retrospectively examined to determine how many of
them were cancer survivors. 200 had Alzheimer’s disease (AD), 89
Mild Cognitive Impairment (MCI), 49 Vascular Dementia (VaD), 25
tauopathies (21 Frontotemporal dementia, 3 Progressive Supranuclear
Palsy, 1 Corticobasal Degeneration), 28 other dementias. 79 subjects
had neither cognitive impairment nor other neurological diseases. Fre-
quency of cancer in these different groups was compared by Chi-
Square. Results: 59 out of 470 subjects were long-term survivors
(cancer diagnosis from at least 5 years) and 6 were short-term survivors.
A medical history of cancer were present in 12 healthy subjects
(15.1%), 30 AD (15%), 7 MCI (7.8%), 7 VaD (14.2%), 6 patients with
tauopathies (24%), 3 patients with other dementias (10.7%). No signif-
icant differences in the frequency of cancer was observed between
healthy aged and demented people. However, a trend towards a higher
percentage of cancer history in patients affected by tauopathy compared
with other dementias was observed. Stratifying by type of neoplasia or
age at cancer occurrence, no significant differences were observed.
Notably, 6 MCI patients were short-term survivors. Conclusions: In
our population, no significant association between dementia and cancer
history was found. Nevertheless, the observed higher prevalence of
cancer history in patients with tauopathies needs to be further studied in
larger populations. The possible biological mechanism underlying this
association could be linked to microtubule and cytoskeleton role in
intracellular signaling, cell shape and replication. The higher preva-
lence of short-time survivors among MCI patients confirms the previous
demonstration of a major risk of cognitive impairment in patients with
cancer, possibly due to the therapy.
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Background: Inconsistent evidence exists for an association of C-reactive
protein (CRP) with dementia. ApoE lipoprotein genotype (4 allele) is
associated with increased risk of dementias. Recent work suggests that
CRP levels are lower in the presence of E4 allele. This analysis investigates
whether E4 status modifies the association between c-reactive protein and
incidence of dementia and cognitive impairment without dementia (D/
CIND). Methods: The association of CRP to 4.5 year incidence of
D/CIND was examined in a cohort of 1,789 Mexican Americans. Dementia
and CIND (n71) were ascertained by neuropsychological, clinical exams
and expert adjudication. APOE, baseline CRP (mg/L) and fasting LDL
values were available for 1,059 subjects; 63 were APOE4. The associ-
ations between CRP and D/CIND incidence were tested in proportional
hazards models with age at diagnosis as the time variable and including
serial adjustment for APOE, LDL, baseline age, gender. Interaction terms
for E4 with CRP and LDL were included. Results: CRP was significantly
lower in those with an E4 allele (adjusted means: 1.82 vs. 3.12, p0.005).
CRP was significantly lower in demented cases with E4 compared to those
without E4 (means: 0.64 vs 3.4, p0.007). Presence of at least one APOE4
allele was associated with an increased risk of D/CIND (HR: 2.13, p0.05)
in a model with age and LDL. CRP was not associated with D/CIND risk
in a model including APOE, LDL, age (HR: 1.03, p0.76). Risk of
D/CIND from CRP was lower in those E4 than in those E4- (HR: E4
0.28: HR: E4-: 0.72, p  0.04). Adjustment for LDL decreased the risk by
36%. Conclusions: In the presence of an E4 allele, higher CRP is protec-
tive for D/CIND; lower CRP increases risk. LDL adjustment indicates CRP
may act in this association by lipid pathways. These results have implica-
tions for therapies in AD that affect CRP levels such as estrogens and
statins.
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Background: Newly generated amyloid  peptide (A) is rapidly
cleared from the brain and this process may be defective in Alzheimer‘s
disease (AD). Insulin degrading enzyme (IDE) is a major brain protease
capable of degrading A but little is known about the sub-cellular
compartment where IDE-A interaction occurs. It has been proposed
that A generation and its oligomerization in AD takes place in mem-
brane regions enriched in cholesterol and glycosphingolipids defined as
lipid-rafts. We hypothesize that membrane -rather than cytosolic- IDE
isoforms are critical in keeping the levels of soluble brain A within a
physiological range. Objective(s): 1. To investigate if proteolitically
active IDE is associated with lipid rafts. 2. To study the interaction of
this IDE isoform with A. Methods: 1. Preparation of membrane
homogenates from cells and brain, alkaline treatment and IDE detection
by western blot. 2. Isolation of lipid rafts from N2a cells, rat and human
brain by Triton X-100 treatment and sucrose gradient flotation. 3.
Detection of IDE in lipid rafts of living cells by immunofluorescence
(IF) using cholera toxin subunit B (CTB) and 1C1 anti-IDE monoclonal
antibody. 4. Depletion of cellular cholesterol with methyl -cyclodex-
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